DEVELOPING
NOTABLE60
CLINICAL TRIALLimited grounding
Partner advances Gubra originated obesity triple agonist peptide into phase 2 - marketscreener.com
A partner company has moved a triple agonist peptide (a drug that works on three different receptors to reduce appetite and weight) that was originally developed by Gubra into Phase 2 testing (the second stage of human trials). The drug targets obesity, joining other similar medications in development.
Analysis
Triple-agonist peptides are the next competitive front behind retatrutide; Gubra-partnered Phase 2 entry expands the field of multi-receptor obesity contenders.
- Gubra-originated triple agonist obesity peptide advanced to Phase 2 by partner
- Asset is a triple receptor agonist targeting obesity
Retatrutide News5d
Read